中医药防治分子靶向治疗药物相关不良反应的研究进展  

Research Progression of Traditional Chinese Medicine for Target Agents Related Adverse Events

作　　者：邓博[1] 贾立群[1] 邓超[1,2] 张亚男 刘青[1] DENG Bo;JIA Liqun;DENG Chao;ZHANG Yanan;LIU Qing(Integrative Oncology Department, China- Japan Friendship Hospital, Beijing 100029, China;Beijing University of Chinese Medicine, Beijing 100029,China)

机构地区：[1]中日友好医院中西医结合肿瘤内科,北京100029 [2]北京中医药大学,北京100029

出　　处：《中华中医药学刊》2018年第7期1580-1583,共4页Chinese Archives of Traditional Chinese Medicine

基　　金：国家自然科学基金项目(81603462);首都卫生发展科研专项项目(首发2018-2-40610);中日友好医院院级项目(2016-1-QN-6,2016-2-QN-16)

摘　　要：分子靶向治疗药物使恶性肿瘤的治疗进入一个新的时代,但相关的不良反应严重影响患者生活质量,导致靶向治疗药物减量或中断,降低抗肿瘤疗效。采用中医药防治靶向药物相关皮疹、手足皮肤反应、腹泻、周围神经病变等,取得了良好的疗效。检索中国期刊全文数据库、万方数据库及Pubmed中关于中药干预靶向药物相关不良反应的临床研究报道,并进行系统综述。Target agents provide new treatment for malignant tumors. However,target agents related adverse events（ AEs） can have a negative impact on the patient＇s quality of life（ QOL）,leading to dose modifications or drug discontinuation and compromising clinical outcome. Traditional Chinese Medicine（ TCM） produced a benefit in prevention and treatment of these AEs. Clinical studies were identified by literature searches in China National Knowledge Infrastructure（ CNKI） database,Wan-Fang Database and Pub Med database and a systematic review of TCM for target agents related AEs was produced.

关 键 词：靶向治疗药物 不良反应 中药 

分 类 号：R2-03[医药卫生—中医学]